
	Where results make sense

Topic: Par Pharmaceutical

Related Topics

Ambroise Par

Par Fabian Lagerkvist

386SPART PAR

Socialisme par en bas

Pars nervosa

Par Pharmaceutical

Pars distalis

Par mangroves

Gabriel Par s Gordillo

par command

Par PA

yid kyi rnam par shes pa

In the News (Sun 15 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Par Pharmaceutical Will Restate Certain Prior Period Results and Delay Filing Its Second Quarter Form 10-Q
		However, Par is unable to estimate at this time the amount of the overstated revenues that may be recovered.
		Par currently has cash, cash equivalents and available for sale securities on hand totaling $183 million and there has been no increase in the company's borrowings during the second quarter.
		Par invites investors and general public to listen to a webcast of the conference call.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/07-05-2006/0004391970&EDATE= (770 words)

	SEC Info - Par Pharmaceutical Companies/Inc - 10-K405 - For 12/31/00 (Site not responding. Last check: )
		Par believes that the issuance of this patent, which establishes the uniqueness of Par's formulation compared to the BMS patent, should significantly help Par's defense in the patent infringement case.
		Par believes that as a result of the BMS patent and the Par patent, it could be more difficult for other generic companies to develop a product that does not infringe either patent.
		Par's counterclaims seek an injunction and an award of compensatory and punitive damages, and may ultimately be tried before a jury.
	www.secinfo.com /drDcf.48u.htm (10725 words)

	Abrika Pharmaceuticals News - Milestones
		Par and Abrika have also entered into an agreement to collaborate in the marketing of five generic products to be developed by Abrika.
		Abrika Pharmaceuticals LLLP is a specialty generic pharmaceutical company engaged in the formulation and commercialization of both controlled release and immediate release products utilizing proprietary drug delivery technologies.
		Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc., and its recently acquired subsidiary, Kali Laboratories, Inc. The company is also developing an additional line of branded pharmaceutical products for specialty markets and expects to introduce the first of these in 2005.
	www.abrika.com /news/news_ParPharm120604.html (628 words)

	RedOrbit - Health - Par Pharmaceutical Reports Sales and Earnings for 2005
		Par acquired the registration from FSC Laboratories, Inc. in February 2005 and began distributing verapamil hydrochloride extended release tablets, a generic version of Isoptin SR.
		Par had earlier announced that it entered into a supply and distribution agreement with GlaxoSmithKline (GSK) in the U.S. to distribute fluticasone propionate nasal spray, which is fully substitutable for GSK's allergy spray Flonase.
		Par had begun shipping the product last week, which is manufactured by a GSK subsidiary; - Par entered into a collaborative agreement with Spectrum Pharmaceuticals, Inc. to develop and market generic drugs, including generic versions of injectable and ophthalmic pharmaceuticals.
	www.redorbit.com /news/health/408887/par_pharmaceutical_reports_sales_and_earnings_for_2005/index.html?source=r_health (1596 words)

	PR Newswire Business News: Par Pharmaceutical Reports First-Quarter Sales and Earnings - MSN Money (Site not responding. Last check: )
		Par was awarded 180 days of marketing exclusivity for being the first to file an Abbreviated New Drug Application containing a paragraph IV certification for the product.
		Par's first-quarter gross margin was 32 percent of sales, compared to 41 percent in 2005.
		Par also began patient enrollment in a Phase IIB study of PAR-101, a narrow-spectrum antibiotic being developed for the treatment of Clostridium difficile-associated diarrhea.
	news.moneycentral.msn.com /provider/providerarticle.asp?feed=PR&Date=20060501&ID=5681869 (1247 words)

	Par Pharmaceutical Resumes Generic Flonase Sales
		Par Pharmaceutical (PRX - news - Cramer's Take) announced Tuesday that it resumed shipment of fluticasone propionate nasal spray, a substitute for GlaxoSmithKline's > (GSK - news - Cramer's Take) Flonase.
		Par had stopped all shipments since Feb. 23 after a temporary restraining order was granted to GSK by the U.S. District Court for the District of Maryland.
		Shares of Par Pharmaceutical rose 32 cents, or 1.1%, to $28.99 Tuesday.
	www.thestreet.com /stocks/pharmaceuticals/10272339.html (134 words)

	PAR Pharmaceutical
		Our goal is to continue the growth that propelled Par into the top echelon of generic drug companies, and simultaneously move forward with the development of a line of branded supportive care therapies for AIDS and cancer patients.
		Par Pharmaceutical Files Form 10-Qs for First and Second Quarters of 2007...
		Par Pharmaceutical Enters into Agreement with Valeant Pharmaceuticals...
	www.parpharm.com /investors/index.jsp (256 words)

	Par Pharmaceutical Companies, Inc. :: Par Pharmaceutical Reports Second-Quarter Sales and Earnings (Site not responding. Last check: )
		Par reported a net loss in the quarter of $.6 million, or $.02 loss per diluted share.
		Par's second-quarter gross margin was 42 percent of sales, compared to 34 percent in 2004.
		Par believes it was first to file an ANDA containing a paragraph IV certification for the product and may be entitled up to 180 days of marketing exclusivity.
	sev.prnewswire.com /biotechnology/20050728/NYTH03528072005-1.html (1283 words)

	GlaxoSmithKline - GlaxoSmithKline, Par Pharmaceutical, Inc. and Pentech Pharmaceuticals, Inc. agree to settle ... (Site not responding. Last check: )
		Par will be entitled to distribute the same product in the U.S. market once another generic version fully substitutable for Paxil® becomes available there.
		In the settlement, Pentech and Par acknowledge that the GSK patent covering the hemihydrate form of paroxetine hydrochloride is valid and enforceable and would be infringed by Pentech's proposed capsule product, for which Pentech has applied for FDA approval.
		Pharmaceutical Resources, Inc., a holding company, develops, manufactures, and distributes generic pharmaceuticals through its wholly owned subsidiary, Par Pharmaceutical.
	www.gsk.com /ControllerServlet?appId=4&pageId=402&newsid=156 (413 words)

	AEGiS-PRn: Pharmaceutical Resources Files ANDA Submission for Megestrol Acetate Oral Suspension
		Par believes that it was the first company to have its ANDA accepted for filing by the FDA, and that it should be entitled to a 180-day period of marketing exclusivity after approval of the product.
		Par strongly believes that its distinct and unique formulation does not infringe the one remaining Bristol Myers Squibb formulation patent.
		However, Par may be excluded from the market for a period of 30 months based on current legislation.
	www.aegis.com /NEWS/PR/1999/Pr991015.html (648 words)

	Crestec Digital Inc. – Portfolio - Par Pharmaceutical (Site not responding. Last check: )
		Par Pharmaceutical, a manufacturer of generic drugs, must serve different market segments with different information.
		Par Pharmaceutical, Inc., a wholly owned subsidiary of Pharmaceutical Resources, Inc., is a manufacturer and distributor of a broad line of generic drugs.
		Par's executive offices, part of its research and development center and a substantial portion of its production facilities are located in Spring Valley, New York.
	www.crestecdigital.com /html/cdi_portfolio_par.html (382 words)

	AEGiS-PRn: Par Pharmaceutical Announces FDA Approval of Megace(R) ES for Anorexia, Cachexia, or an Unexplained, ...
		WOODCLIFF LAKE, N.J., July 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that the U.S. Food and Drug Administration (FDA) has approved Megace(R) ES (megestrol acetate), a concentrated oral suspension for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).
		"Par Pharmaceutical is committed to the science of improving treatment solutions for patients," said Scott Tarriff, president and chief executive officer.
		Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc., and its recently acquired subsidiary, Kali Laboratories, Inc. The company also is developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace ES.
	www.aegis.com /NEWS/PR/2005/PR050711.html (1318 words)

	PRX Stock Quote - Par Pharmaceutical Cos Inc Stock Quote - PRX Quote - PRX Stock Price
		Par Pharmaceutical Files Form 10-Qs for First and Second Quarters of 2007 - PR Newswire
		Par Invites Public to Listen to Webcast of its September 28 Analysts' Meeting - PR Newswire
		Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 - PR Newswire
	www.marketwatch.com /quotes/prx?dist=yhoostoryquote (368 words)

	Pharmaceutical Resources News
		Par Pharmaceutical Companies, Inc. today announced that its wholly-owned subsidiary, Kali Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug...
		Par Pharmaceutical Companies, Inc. will be presenting at the 2006 Friedman Billings Ramsey Growth Investor Conference on Thursday, June 1, at 10:30 am EDT at The Grand Hyatt New York.
		Par Pharmaceutical Companies, Inc. invites investors and the general public to listen to a webcast of a conference call with investment analysts at 8:30 a.m.
	www.topix.net /com/prx (667 words)

	Par Pharmaceutical Companies, Inc. - Spectrum Pharmaceuticals, Inc.
		In Februrary 2005, Spectrum entered into a strategic alliance with Par Pharmaceutical Companies, Inc. (NYSE: PRX) for the sale and distribution of the Company's generic drugs including a filing done with paragraph IV certification for sumatriptan injection.
		Par also has agreed to make an equity investment in Spectrum, within 24 months of the agreement, at Spectrum's request.
		Par's expertise in the field of generics, financial strength and drug distribution skills should enhance and expedite the development of Spectrum's generics program.
	www.spectrumpharm.com /Par_Pharmaceutical.html (203 words)

	[No title]
		September 15 is the Deadline for Investors of Par Pharmaceutical Companies, Inc....
		Par Pharmaceutical Companies, Inc. (PRX) is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc. (Par), is in the business of manufacturing and distributing generic and branded drugs in the United States.
		Par Pharmaceutical Companies, Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
	today.reuters.com /stocks/Overview.aspx?symbol=PRX.N&chart=7 (531 words)

	RedOrbit - Health - Par Pharmaceutical's Partner Receives Final Approval To Market Mirtazapine Orally Disintegrating ...
		The product was developed by Par's wholly-owned subsidiary, Kali Laboratories, Inc. Mirtazapine ODT is the generic version of Organon's Remeron SolTab(R) and is indicated for the treatment of major depressive disorder.
		Amide Pharmaceutical, Inc., a subsidiary of Actavis Group hf, located in Little Falls, New Jersey, develops, manufactures and markets a select line of high quality pharmaceuticals.
		Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets.
	www.redorbit.com /news/display?id=227405&source=r_health (360 words)

	Medical World Communications
		Potassium chloride 20mEq is the generic equivalent of Key Pharmaceutical's K-Dur(R) 20 tablet, a potassium supplement used in the treatment of hypokalemia, digitalis intoxication and hypokalemic familial periodic paralysis.
		Under the terms of the agreement, Par has exclusive rights to market, sell and distribute Eurand's potassium chloride 20mEq tablets in the U.S. Eurand is responsible for manufacturing, and will receive an upfront license fee and a share of the profits from sales of the product.
		Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies.
	www.mwc.com /NewsfeedArticle.cfm?NewsID=7244 (370 words)

	Par Pharmaceutical Companies, Inc. information and related industry information from Hoover's
		Par Pharmaceutical Companies is your insurance company's resource for cheaper drugs.
		Par manufactures some of its own products, but in many cases, it distributes drugs manufactured by strategic partners.
		Its Megace ES won FDA approval in 2005 to treat anorexia and severe weight loss associated with AIDS; the drug is a version of a compound owned by Bristol-Myers Squibb.
	www.hoovers.com /par-pharmaceutical-companies/--ID__11152--/free-co-factsheet.xhtml (462 words)

	globeandmail.com : globeinvestor.com : Spectrum Announces Strategic Alliance with Par Pharmaceutical Companies, Inc. ...
		Par also has agreed to make an equity investment in Spectrum during the next 24 months, at Spectrum's request.
		Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs.
		Representatives of Par provided the information under "About Par Pharmaceutical" to Spectrum and therefore, Spectrum has not verified the accuracy of those statements.
	www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20050706&archive=prnews&slug=2005_07_06_06_1443_1401163 (797 words)

	Par, Roxane resume shipment of generic Flonase \| newratings.com (Site not responding. Last check: )
		Par Pharmaceutical quote - chart - all headlines - investor relations - analyst actions - add to watchlist - current ratings
		NEW YORK, March 8 (newratings.com) — Par Pharmaceuticals Co (PRX) and Roxanne Laboratories, a unit of Germany’s Boehringer Ingelheim, Tuesday announced that they had resumed the sale of the generic version of GlaxoSmithKline’s (PZJ.FSE) Flonase nasal spray.
		Par Pharmaceutical’s share price appreciated $0.27 to $28.94 in afternoon trading on the New York Stock Exchange on Tuesday, while American depositary shares of London-based GlaxoSmithKline rose $0.21 to $52.34.
	www.newratings.com /analyst_news/article_1223006.html (305 words)

	Par Pharmaceutical gains US approval for Megace ES - Pharmaceutical Business Review
		New York-based Par Pharmaceutical has received approval from the FDA for its Megace ES compound in the treatment of anorexia, cachexia or unexplained weight loss in AIDs sufferers.
		According to the company, the new Megace ES is an advanced formulation of megestrol acetate oral suspension, an appetite stimulant most commonly prescribed by physicians.
		Par and MN Pharmaceuticals form injectable generics alliance
	www.pharmaceutical-business-review.com /article_news.asp?guid=DA8FF838-0284-48FD-9CF1-8E1B34E06AD3 (322 words)

	Partners - Nastech
		On June 23, 2006, Nastech and Amylin Pharmaceuticals, Inc. entered into an agreement to develop a nasal spray form of exenatide for treatment of Type II Diabetes and various therapeutic areas.
		Under the terms of the agreement with Par Pharmaceutical, Nastech will obtain FDA approval, manufacture and supply finished generic calcitonin-salmon intranasal spray product to Par Pharmaceutical.
		QOL (quality of life) Medical is a specialty pharmaceutical company dedicated to improving quality of life for patients, their families and caregivers.
	www.nastech.com /nastech/partners (1951 words)

	Healthcare Sales & Marketing Network News: Par Pharmaceutical Names John A. MacPhee Senior Vice President, Branded ...
		MacPhee will be instrumental in Par's successful development of a new line of branded pharmaceutical products for specialty markets.
		MacPhee was a team leader at Rhone- Poulenc Rorer (RPR) Pharmaceuticals, Inc., where he began his career in the pharmaceutical industry in 1992.
		Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products for specialty markets and expects to introduce the first of these in 2005.
	salesandmarketingnetwork.com /news_release.php?ID=2002786&... (555 words)

	Pharmacy Choice - Pharmaceutical News - Par Pharmaceutical Announces Results of Phase II Proof-of-Concept Study with ...
		Par's recently approved Megace ES (megestrol acetate) 625 mg/ 5 mL concentrated oral suspension was not the dosage strength tested in this study.
		Par's development program evaluated seven doses of concentrated megestrol acetate, including a 575 mg/5 mL and a 625 mg/5 mL dose.
		This study of the 575 mg/5 mL dose of concentrated megestrol acetate was initiated prior to the determination that the 625 mg/5 mL dosage strength would be the marketed dose.
	www.pharmacychoice.com /News/article.cfm?Article_ID=9676 (880 words)

	Datamonitor ComputerWire - Par Pharmaceutical Companies, Inc. - Company News & Research
		Par Pharmaceutical Companies is a holding company whose subsidiary, Par Pharmaceutical, develop and markets generic drugs for the nervous system and cardiovascular diseases.
		Par Pharmaceutical Companies is headquartered in Spring Valley, New York and employs about 500 people.
		The net profit was $122.5 million during fiscal year 2003, an increase of 54.2% over 2002.
	www.computerwire.com /companies/company/?pid=CA378989-2024-44F6-A76F-A608E7113C1E (130 words)

	Healthcare Sales & Marketing Network News: Par Pharmaceutical Names Gerard A. Martino Chief Financial Officer (Site not responding. Last check: )
		Par Pharmaceutical Names Gerard A. Martino Chief Financial Officer
		Martino joins Par from Schering-Plough Corporation where he served as vice president, global materials management.
		"Par is fortunate to have attracted an experienced financial executive of Jerry's caliber," said Mr.
	salesandmarketingnetwork.com /news_release.php?ID=2010437 (467 words)

	Free Info About Pharmaceutical Reviews (Site not responding. Last check: )
		Authorized Generics, Their Role in the Pharmaceutical Marketplace, and the FTC Study" on Thursday, September 14 from noon to 1:30 pm EST.
		An anthropology professor at the pharmaceutical information and MORTGAGE FEES is rainier than last April, she said.
		But as with EVERY pharmaceutical product made to help relieve pain or discomfort there are risks, and hormone therapy is not without them.
	www.drugs365.info (501 words)

Try your search on: Qwika (all wikis)